Kipp Weiskopf: Our work on macrophage immunotherapy

Kipp Weiskopf, Valhalla Whitehead Fellow at Whitehead Institute and Co-Founder and Scientific Advisory Board Co-Chair at DEM Biopharma, shared a post by Whitehead Institute on their X/Twitter and added:

”Thanks for sharing our work on macrophage immunotherapy! We hope it makes a difference to patients with cancers bearing driver mutations!”

Quoting Whitehead Institute’s post:

”A novel drug screen developed by Kipp Weiskopf  and the Hata lab at MGH identifies existing drugs that can help prime lung cancer cells for destruction by macrophages.”

Read further.
Source: Kipp Weiskopf/X and Whitehead Institute/X

About OncoDaily 

OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.

OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.

The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we”.